European countries are now preparing for the scenario of at least two vaccines against Covid-19 available from the first weeks of 2021. The most advanced is the candidate of the American-German duo Pfizer-BioNTech, which announced in a press release on Wednesday that it had reached the threshold of 170 patients required in its phase 3 clinical trial. According to its latest results, the vaccine, delivered in two doses at 21 day intervals, displays an efficiency rate of 95%, “Constant by sex, ethnicity and age”. Very encouragingly, protection reaches 94% among those over 65.
The main side effects observed are fatigue (3.8% of people vaccinated) and headaches (2%). Pfizer specifies that it will ask “In a few days” an emergency use authorization to the American Medicines Agency (FDA), and says it shares its results with other global health agencies, including the European Medicines Agency (EMA).